Vulvar Cancer: Pipeline Review H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Vulvar Cancer - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 7 and 2 respectively.

Companies Mentioned

Bristol-Myers Squibb Co Cutanea Life Sciences Inc IRX Therapeutics Inc ISA Pharmaceuticals BV MedImmune LLC Merck KGaA Ono Pharmaceutical Co Ltd Transgene SA

Key Topics Covered

Introduction Report Coverage Vulvar Cancer - Overview Vulvar Cancer - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Vulvar Cancer - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Vulvar Cancer - Companies Involved in Therapeutics Development

For more information about this report visit https://www.researchandmarkets.com/research/9662bm/vulvar_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005511/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 04:53 AM/DISC: 06/06/2018 04:53 AM


Update hourly